Sustained remission of Cronkhite-Canada syndrome after corticosteroid and mesalazine treatment: A case report

BACKGROUND Cronkhite-Canada syndrome(CCS)is a rare disease of unknown etiology.The optimal treatment for CCS remains unknown.Treatment with corticosteroids is considered the mainstay treatment because of its high efficacy,but the therapeutic strategy for steroid-resistant CCS is not yet established.CASE SUMMARY This is the case of an 81-year-old woman who was diagnosed with CCS.Given her severe diarrhea,nausea,vomiting,and hypoproteinemia,hormone therapy(40 mg/d)was administered,and the symptoms improved within 1 wk.After 3 mo,the patient had no obvious symptoms.The polyps were significantly reduced on review gastroscopy and colonoscopy,thus hormone reduction gradually began.The hormone level was maintained at 10 mg/d after 6 mo.Despite the age of the patient and the side effects of hormones,the patient had no obvious discomfort.However,hormone drugs were discontinued,and mesalazine was administered orally at 3 g/d.The patient's symptoms continued to improve after a follow-up of 5 years.CONCLUSION Corticosteroids and mesalazine are potential treatment options for CCS.

Efficacy and safety of Xileisan combined with mesalazine for ulcerative colitis:A meta-analysis and trial sequential analysis

BACKGROUND The benefits and risks of Xileisan(XLS)in the treatment of ulcerative colitis(UC)remain unclear.AIM The present study aimed to evaluate the efficacy and safety of the combination of XLS and mesalazine when treating UC.METHODS We searched eight databases for clinical trials evaluating the combination of XLS and mesalazine in the treatment of UC,up to January 2024.Meta-analysis and trial sequential analysis(TSA)were performed using Revman 5.3 and TSA 0.9.5.10 beta,respectively.RESULTS The present study included 13 clinical studies involving 990 patients,of which 501 patients received XLS combined with mesalazine while 489 patients received mesalazine alone.The meta-analysis showed that,in terms of efficacy,the combination of XLS and mesalazine significantly improved the clinical efficacy rate by 22%[risk ratio(RR)=1.22;95%CI:1.15–1.28;P<0.00001]and mucosal improvement rate by 25%(RR=1.25;95%CI:1.12–1.39;P=0.0001),while significantly reducing the duration of abdominal pain by 2.25 days[mean difference(MD)=-2.25;95%CI:-3.35 to-1.14;P<0.0001],diarrhea by 2.06 days(MD=-2.06;95%CI:-3.92 to-0.20;P=0.03),hematochezia by 2.32 days(MD=-2.32;95%CI:-4.02 to-0.62;P=0.008),tumor necrosis factor alpha by 16.25 ng/mL(MD=-16.25;95%CI:-20.48 to-12.01;P<0.00001),and interleukin-6 by 14.14 ng/mL(MD=-14.14;95%CI:-24.89 to-3.39;P=0.01).The TSA indicated conclusiveness in the meta-analysis of the efficacy endpoints.In terms of safety,the meta-analysis revealed that the combination of XLS and mesalazine did not increase the occurrence of total and gastrointestinal adverse events,abdominal distension,and erythema(P>0.05).The TSA showed non conclusive findings in the meta-analysis of the safety endpoints.Harbord’s test showed no publication bias(P=0.734).CONCLUSION Treatment with XLS alleviated the clinical symptoms,intestinal mucosal injury,and inflammatory response in patients with UC,while demonstrating good safety.

RETRACTED: Determination of the Mesalazine Solubility at Biorelevant Temperature

Short Retraction NoticeThis article has been retracted to straighten the academic record. In making this decision the Editorial Board follows COPE's Retraction Guidelines. The aim is to promote the circulation of scientific research by offering an ideal research publication platform with due consideration of internationally accepted standards on publication ethics. The Editorial Board would like to extend its sincere apologies for any inconvenience this retraction may have caused. The full retraction notice in PDF is preceding the original paper, which is marked "RETRACTED".

Proposed case of mesalazine-induced cardiomyopathy in severe ulcerative colitis

Five-amino salicylic acids are recommended for use in the management of inflammatory bowel disease,cardiac complications are a rare although recognised phenomenon.This report aims to highlight this serious but rare adverse reaction.We report here a case of a young man presenting with cardiogenic shock in the context of recent mesalazine treatment in severe ulcerative colitis.

Gastroenterology case report of mesalazine-induced cardiopulmonary hypersensitivity

Mesalazine is a 5-aminosalicylic acid derivative that has been widely used to treat patients with inflammatory bowel disease. Accumulating evidence indicates that mesalazine has a very low rate of adverse drug reactions and is well tolerated by patients. However, a few cases of pulmonary and cardiac disease related to mesalazine have been reported in the past, though infrequently, preventing clinicians from diagnosing the conditions early. We describe the case of a 32-yearold man with ulcerative colitis who was admitted with a two-month history of persistent fever following mesalazine treatment initiated 14 mo earlier. At the time of admission, mesalazine dose was increased from 1.5 to 3.0 g/d, and antibiotic therapy was started with no improvement. Three weeks after admission, the patient developed dyspnea, non-productive cough, and chest pain. Severe eosinophilia was detected in laboratory tests, and a computed tomography scan revealed interstitial infiltrates in both lungs, as well as a large pericardial effusion. The bronchoalveolar lavage reported a CD4/CD8 ratio of 0.5, and an increased eosinophil count. Transbronchial biopsy examination showed a severe eosinophilic infiltrate of the lung tissue. Mesalazine-induced cardiopulmonary hypersensitivity was suspected after excluding other possible etiologies. Consequently, mesalazine treatment was suspended, and corticosteroid therapy was initiated, resulting in resolution of symptoms and radiologic abnormalities. We conclude that mesalazine-induced pulmonary and cardiac hypersensitivity should always be considered in the differential diagnosis of unexplained cardiopulmonary symptoms and radiographic abnormalities in patients with inflammatory bowel disease.

Mucosal healing effect of mesalazine granules in naproxen-induced small bowel enteropathy

AIM:To investigate the effect of mesalazine granules on small intestinal injury induced by naproxen using capsule endoscopy (CE).METHODS:This was a single center,non-randomized,open-label,uncontrolled pilot study,using the PillCam SB CE system with RAPID 5 software.The Lewis Index Score (LIS) for small bowel injury was investigated to evaluate the severity of mucosal injury.Arthropathy patients with at least one month history of daily naproxen use of 1000 mg and proton pump inhibitor co-therapy were screened.Patients with a minimum LIS of 135 were eligible to enter the 4-wk treatment phase of the study.During this treatment period,3 × 1000 mg/d mesalazine granules were added to ongoing therapies of 1000 mg/d naproxen and 20 mg/d omeprazole.At the end of the 4-wk combined treatment period,a second small bowel CE was performed to re-evaluate the enteropathy according to the LIS results.The primary objective of this study was to assess the mucosal changes after 4 wk of mesalazine treatment.RESULTS:A total of 18 patients (16 females),ranging in age from 46 to 78 years (mean age 60.3 years) were screened,all had been taking 1000 mg/d naproxen for at least one month.Eight patients were excluded from the mesalazine therapeutic phase of the study for the following reasons:the screening CE showed normal small bowel mucosa or only insignificant damages (LIS < 135) in five patients,the screening esophagogastroduodenoscopy revealed gastric ulcer in one patient,capsule technical failure and incomplete CE due to poor small bowel cleanliness in two patients.Ten patients (9 female,mean age 56.2 years) whose initial LIS reached mild and moderate-to-severe enteropathy grades (between 135 and 790 and ≥ 790) entered the 4-wk therapeutic phase and a repeat CE was performed.When comparing the change in LIS from baseline to end of treatment in all patients,a marked decrease was seen (mean LIS:1236.4 ± 821.9 vs 925.2 ± 543.4,P=0.271).Moreover,a significant difference between pre-and post-treatment mean total LIS was detected in 7 patients who had moderate-tosevere enteropathy gradings at the inclusion CE (mean LIS:1615 ± 672vs 1064 ± 424,P=0.033).CONCLUSION:According to the small bowel CE evaluation mesalazine granules significantly attenuated mucosal injuries in patients with moderate-to-severe enteropathies induced by naproxen.

Molecular basis of the potential of mesalazine to prevent colorectal cancer

Patients with ulcerative colitis (UC) and Crohn's disease (CD) are at increased risk for developing colorectal cancer (CRC), and this is believed to be a result of chronic inflammation. Although conclusive evidence is still missing, both epidemiological and experimental observations suggest that certain drugs used to treat inflammation, such as mesalazine, can reduce the incidence of colitis-associated CRC. Therefore, in recent years, several studies have been conducted to dissect the mechanisms by which mesalazine interferes with CRC cell growth and survival. This review summarizes the current information on the molecular mechanisms that underlie the antineoplastic action of mesalazine.

Mesalazine治疗溃疡性结肠炎有效

作者对87例轻到中度活动性溃疡性结肠炎口服以酸碱度敏感的聚合物糖衣制成的mesalazine进行了双盲对照试验,以评价该药的安全性和功效。这些病人随机接受mesalazine4.8g/d(38例)、1.6g/d(11例)及安慰剂(30例),均用药6周。4.8g/d组与安慰剂组的疾病特征均相似。1.

Clinical Efficacy on the Treatment of Chronic Colitis with Feng-Liao-Chang-Wei-Kang Granules Combined with Mesalazine

[Objectives]To analyze the clinical effect of Feng-Liao-Chang-Wei-Kang Granule combined with mesalazine on chronic colitis.[Methods]120 patients with chronic enteritis admitted to Qionghai Hospital of Traditional Chinese Medicine from October 2020 to March 2022 were selected as the research objects,and were randomly divided into combined group(62 cases)and conventional group(58 cases).Patients in the conventional group were treated with oral mesalazine on the basis of conventional treatment,while patients in the combined group were treated with Feng-Liao-Chang-Wei-Kang Granule combined with mesalazine.The clinical efficacy,inflammatory factor level,colonic mucosal lesion degree,quality of life and TCM syndrome scores of the two groups were compared.[Results]The total clinical effective rate in the combined group was higher than that in the conventional group(P<0.05).After treatment,the levels of inflammatory factors in the two groups were lower than those before treatment,and the levels of interleukin-6(IL-6),C-reactive protein(CRP)and tumor necrosis factor-α(TNF-α)in the combined group were lower than those in the conventional group(P<0.001).After treatment,the Baron and Geboes scores of the two groups were lower than those before treatment,and the Baron and Geboes scores of the combined group were lower than those of the conventional group(P<0.001).After treatment,the scores of quality of life in the two groups were higher than those before treatment,while the scores of TCM syndromes were lower than those before treatment.The scores of quality of life in the combined group were higher than those in the conventional group(P<0.001).[Conclusions]Feng-Liao-Chang-Wei-Kang Granule combined with mesalazine can obviously improve the curative effect,reduce the level of inflammatory factors,improve the degree of colonic mucosal lesions and improve the quality of life of patients with chronic colitis,which is worthy of popularization and application in clinical practice.

Clinical observation of Baitou Weng Decoction combined with mesalazine sustained-release tablets in treating heat-toxic and smoldering ulcerative colitis

Objective:To observe the clinical efficacy of Baitou Weng Decoction combined with mesalazine sustained-release tablets in the treatment of ulcerative colitis with febrile heat and its effect on immune function and serum inflammatory factors.Methods: A total of 84 patients with ulcerative colitis were randomly divided into control group and treatment group, with 42 cases in each group. The control group was given mesalazine sustained-release tablets orally, while the treatment group was given Baitou Weng Decoction and mesalazine sustained-release tablets orally. The treatment period was 30 days and the patients were followed up for 3 months. After treatment, the clinical efficacy, quality of life, immune function and serum inflammatory factors of the two groups were observed.Results: The effective rate of treatment group (90.47%) was higher than that of control group (73.81%) (P<0.05);compared with before treatment, the scores of inflammatory bowel disease quality of life questionnaire scale in both groups were significantly improved (P<0.05), and the difference between the two groups was significant (P<0.05);after treatment, the plasma CD4+/CD8+ ratio and NK+ levels in both groups were significantly higher than those before treatment (P<0.05), and the treatment group was changed. The serum levels of tumor necrosis factor-α, interleukin-17 and interleukin-23 were significantly decreased in both groups after treatment (P<0.05), and the improvement was more significant in the treatment group (P<0.05). No significant adverse reactions were observed in the treatment group.Conclusions: Modified Baitou Weng Decoction combined with mesalazine in the treatment of heat-toxic and incandescent ulcerative colitis can significantly improve the clinical efficacy, improve the quality of life of patients, effectively regulate the expression level of serum inflammatory factors in ulcerative colitis patients, promote the recovery of patients' immune function, and have high drug safety.

Use of the ulcerative colitis endoscopic index of severity and Mayo endoscopic score for predicting the therapeutic effect of mesalazine in patients with ulcerative colitis

Objective:The ulcerative colitis endoscopic index of severity(UCEIS)and the Mayo endoscopic score(MES)are developed as objective methods of evaluating endoscopic severity in patients with ulcerative colitis(UC).The aim of this study is to investigate the diagnostic accuracy of the UCEIS and MES in predicting the patient's response to mesalazine.Methods:Consecutive patients with UC who had undergone colonoscopy within 1 month before starting mesalazine between October 2011 and July 2016 were retrospectively collected at the Department of Gastroenterology,Sir Run Run Shaw Hospital,Zhejiang University School of Medicine.The median follow-up was 81 months,and all the data were analyzed in January 2021.The primary outcome was the need for step-up treatment,which included the use of corticosteroids,immunomodulatory,or surgery during admission and follow-up.Data were analyzed using the c2 or Fisher exact test,Spearman test,t-test,and ManneWhitney U test.Results:Totally,65 patients were enrolled,of whom 12(18.5%)needed step-up treatment due to nonresponse to mesalazine.The UCEIS score,MES,and the ulcerative colitis disease activity index(UCDAI)score were significantly higher in patients who had nonresponse to mesalazine(UCEIS score:6.92±0.69 vs.4.45±1.17,p<0.001;MES:2.67±0.49 vs.2.15±0.69,p=0.024;UCDAI score:9.33±1.87 vs.6.70±2.38,p=0.002).In the multivariate analysis,the UCEIS score(OR=25.65,95%CI:3.048 e45.985,p=0.003),UCDAI score(OR=1.605,95%CI:1.144e2.254,p=0.006),and C-reactive protein level(OR=1.056,95%CI:1.006e1.108,p=0.026)were independent risk factors of nonresponse.The area under the ROC curve of UCEIS was 0.95,with a sensitivity of 100%and specificity of 84.6%,a cut-off value of 6,which outperformed the MES with an area under the ROC curve of 0.70.When the UCEIS score≥6,60%of patients eventually needed step-up treatment.Conclusions:The UCEIS is a useful instrument for predicting the therapeutic effect in patients with UC treated with mesalazine.The high probability of mesalazine treatment failure and benefits of other therapies should be discussed in patients with baseline UCEIS score≥6.

Mesalazine(美沙拉嗪栓剂)塞肛是治疗慢性放射性直肠炎安全有效的方法

为评价慢性放射性直肠炎(chronic radiation proctitis, CRP)患者使用美沙拉嗪栓剂治疗的疗效,本研究选取2010年1月至2013年12月在广西医科大学第二附属医院消化内科就诊的15例CRP患者,给予美沙拉嗪栓剂塞肛治疗(每天2次,每次0.5 g),总疗程为24周,观察患者临床症状的改善情况及肠黏膜的修复情况。结果表明,CRP患者症状总积分显著低于美沙拉嗪栓剂治疗前,差异具有统计学意义(p<0.01);用药后,血便、大便次数及里急后重症状积分均显著低于治疗前,差异具有统计学意义(p<0.01);而腹痛积分治疗前后比较,差异不具有统计学差异(p=0.068)。治疗后黏膜愈合情况较治疗前良好,治疗前后镜下病变等级资料比较,差异具有统计学意义(Z=3.23,p=0.014)。综上所述,美沙拉嗪栓剂塞肛是治疗慢性放射性直肠炎安全有效的方法。

Five commonly used traditional Chinese medicine formulas in the treatment of ulcerative colitis:A network meta-analysis

BACKGROUND Currently,traditional Chinese medicine(TCM)formulas are commonly being used as adjunctive therapy for ulcerative colitis in China.Network meta-analysis,a quantitative and comprehensive analytical method,can systematically compare the effects of different adjunctive treatment options for ulcerative colitis,providing scientific evidence for clinical decision-making.AIM To evaluate the clinical efficacy and safety of commonly used TCM for the treatment of ulcerative colitis(UC)in clinical practice through a network metaanalysis.METHODS Clinical randomized controlled trials of these TCM formulas used for the adjuvant treatment of UC were searched from the establishment of the databases to July 1,2022.Studies that met the inclusion criteria were screened and evaluated for literature quality and risk of bias according to the Cochrane 5.1 standard.The methodological quality of the studies was assessed using ReviewManager(RevMan)5.4,and a funnel plot was constructed to test for publication bias.ADDIS 1.16 statistical software was used to perform statistical analysis of the treatment measures and derive the network relationship and ranking diagrams of the various intervention measures.RESULTS A total of 64 randomized controlled trials involving 5456 patients with UC were included in this study.The adjuvant treatment of UC using five TCM formulations was able to improve the clinical outcome of the patients.Adjuvant treatment with Baitouweng decoction(BTWT)showed a significant effect[mean difference=36.22,95%confidence interval(CI):7.63 to 65.76].For the reduction of tumor necrosis factor in patients with UC,adjunctive therapy with BTWT(mean difference=−9.55,95%CI:−17.89 to−1.41),Shenlingbaizhu powder[SLBZS;odds ratio(OR)=0.19,95%CI:0.08 to 0.39],and Shaoyao decoction(OR=−23.02,95%CI:−33.64 to−13.14)was effective.Shaoyao decoction was more effective than BTWT(OR=0.12,95%CI:0.03 to 0.39),SLBZS(OR=0.19,95%CI:0.08 to 0.39),and Xi Lei powder(OR=0.34,95%CI:0.13 to 0.81)in reducing tumor necrosis factor and the recurrence rate of UC.CONCLUSION TCM combined with mesalazine is more effective than mesalazine alone in the treatment of UC.

乌蔹莓灌肠对远端溃疡性结肠炎患者的临床疗效

目的探讨乌蔹莓灌肠对远端溃疡性结肠炎患者的临床疗效。方法60例患者随机分为对照组和观察组,每组30例,对照组给予美沙拉嗪肠溶片,观察组在对照组基础上加用乌蔹莓灌肠,疗程8周。检测临床疗效、生活质量评分、DAI评分、Mayo活动指数、肠黏膜屏障功能指标(DAO、ET、D-乳酸)、肠道菌群(双歧杆菌、乳酸杆菌、大肠杆菌、肠球菌)、炎症因子(IL-10、IL-6、TNF-α)、安全性指标变化。结果观察组总有效率高于对照组(P<0.05)。治疗后,观察组生活质量评分、IL-10升高(P<0.05),DAI评分、Mayo活动指数、肠黏膜屏障功能指标、IL-6、TNF-α降低(P<0.05),双歧杆菌、乳酸杆菌增加(P<0.05),大肠杆菌、肠球菌减少(P<0.05),并比对照组更明显(肠球菌除外)(P<0.05)。2组未发现不良反应。结论乌蔹莓灌肠可安全有效地改善远端溃疡性结肠炎患者DAI评分和Mayo活动指数,其机制可能与调节菌群稳态、修复肠黏膜屏障、抑制炎症因子释放有关。

枯芩与条芩提取物对湿热型溃疡性结肠炎大鼠的药效学比较研究

目的比较枯芩、条芩提取物对湿热型溃疡性结肠炎(UC)大鼠模型的药效学差异。方法50只健康SD大鼠随机分为5组:正常组、模型组、枯芩组、条芩组和美莎拉嗪组,每组10只。采用高脂高糖饲料喂养+高度白酒灌胃+5%葡聚糖硫酸钠(DSS)联合诱导法,建立湿热型UC大鼠模型;各组分别于造模第1天开始灌胃给药,枯芩组、条芩组给药剂量均为5.25 g·kg^(-1)·d^(-1),美沙拉嗪组给药剂量为0.266 g·kg^(-1)·d^(-1),正常组、模型组灌服等体积生理盐水。连续给药28 d。观察大鼠一般情况;评价大鼠体质量变化和疾病活动指数(DAI)评分;称取大鼠结肠质量,量取结肠长度,并计算结肠单位长度质量;进行大鼠结肠组织HE染色和PAS染色,观察大鼠结肠组织病理学变化;Elisa法检测大鼠血清白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、白介素-1β(IL-1β)、转化生长因子-β_(1)(TGF-β_(1))炎症因子水平。结果与正常组比较,模型组大鼠的体质量显著降低,结肠长度显著缩短,DAI评分、结肠质量、结肠单位长度质量和血清IL-6、TNF-α、IL-1β水平均显著增加,TGF-β_(1)水平显著降低(P<0.01);结肠组织上皮层发生脱落,边缘散乱,隐窝不清晰,黏膜层有水肿,炎症细胞浸润且入侵黏膜下层,肠腺紊乱。与模型组比较,枯芩组、条芩组、美沙拉嗪组大鼠上述指标和相关症状均有明显改善(P<0.05,P<0.01);与枯芩组比较,条芩组、美沙拉嗪组在增加结肠单位长度质量、降低DAI评分、改善炎症因子水平方面均优于枯芩组(P<0.05或P<0.01)。结论枯芩、条芩提取物对湿热型UC大鼠均有较好的改善作用,且条芩优于枯芩。

Enhancing ulcerative colitis treatment with traditional Chinese medicine

Inflammatory bowel disease,particularly ulcerative colitis(UC),poses significant treatment challenges due to its chronic nature and potential for severe complications.This editorial reviews a recent network meta-analysis that evaluated the efficacy of and highlighted the superior outcomes achieved by combining each of five traditional Chinese medicine(TCM)formulations with mesalazine for the adjuvant treatment of UC.Clinical outcomes included enhanced mucosal healing,improved quality of life,and reduced recurrence rates.Additionally,the combination therapy resulted in a lower incidence of adverse reactions compared with mesalazine monotherapy.Despite these promising results,limitations such as variability in study quality and TCM dosage highlight the need for further highquality,large-sample,multicenter randomized controlled trials.This editorial underscores the potential of TCM in enhancing UC management and calls for more rigorous research to substantiate these findings and refine clinical guidelines.

肠炎宁颗粒联合美沙拉嗪对溃疡性结肠炎患者肠道菌群、炎症因子和UCEIS的影响

目的探讨肠炎宁颗粒联合美沙拉嗪治疗对溃疡性结肠炎(UC)患者肠道菌群、炎症因子和内镜下严重程度指数(UCEIS)的影响。方法选取UC患者90例,随机均分为对照组(美沙拉嗪治疗)和观察组(美沙拉嗪+肠炎宁治疗),比较两组症状消失时间、肠道菌群数量、炎症因子水平、内镜下严重程度指数(UCEIS)和Mayo评分。结果治疗后,观察组症状消失时间短于对照组(P<0.05)。与治疗前比较,治疗后两组炎症因子水平、有害菌数量、UCEIS、Mayo评分降低,益生菌数量升高,且观察组较对照组更为显著(P<0.05)。结论肠炎宁颗粒联合美沙拉嗪治疗UC可改善症状和病情严重程度,同时调节肠道菌群平衡和降低炎症因子水平。

甘草泻心汤加减联合美沙拉嗪对溃疡性结肠炎肠道功能屏障及色氨酸代谢的影响分析

目的探讨甘草泻心汤加减联合美沙拉嗪对溃疡性结肠炎(Ulcerative colitis, UC)患者肠道功能屏障及色氨酸代谢的影响。方法选择医院于2019年4月—2021年4月就诊的UC患者142例,依据随机数字表法随机分为观察组(71例)与对照组(71例)。对照组患者给予美沙拉嗪治疗,观察组在对照组基础上结合甘草泻心汤加减治疗。两组治疗疗程12周。比较两组治疗12周临床疗效,治疗前与治疗12周肠道黏膜病变严重程度(改良Mayo评分和Geboes指数)、肠道屏障功能[内毒素、二胺氧化酶(Diamine oxidase, DAO)和D-乳酸]、色氨酸代谢[犬尿氨酸(Kynurenine, Kyn)、犬尿喹啉酸(Kynurenic acid, KynA)和喹啉酸(QuinA)]及药物不良反应。结果观察组UC患者治疗总有效率(91.55%,65/71)高于对照组(74.65%,53/71)(P<0.05)。两组治疗12周UC患者改良Mayo评分和Geboes指数较治疗前降低(P<0.05);观察组治疗12周UC患者改良Mayo评分和Geboes指数低于对照组(P<0.05)。两组治疗12周UC患者内毒素、DAO和D-乳酸水平较治疗前降低(P<0.05);观察组治疗12周UC患者内毒素、DAO和D-乳酸水平低于对照组(P<0.05)。两组治疗12周UC患者QuinA/Kyn较治疗前降低,而KynA/QuinA和KynA/Kyn较治疗前升高(P<0.05);观察组治疗12周UC患者QuinA/Kyn低于对照组,而KynA/QuinA和KynA/Kyn高于对照组(P<0.05)。两组治疗12周UC患者IBDQ评分较治疗前增加(P<0.05);观察组治疗12周UC患者IBDQ评分高于对照组(P<0.05)。两组患者用药期间均未发生明显不良反应。结论甘草泻心汤加减联合美沙拉嗪对UC患者疗效良好,可减轻患者肠道黏膜病变严重程度,改善患者肠道屏障功能和色氨酸代谢。

实炎方对湿热蕴肠型溃疡性结肠炎患者的临床疗效

目的探讨实炎方对湿热蕴肠型溃疡性结肠炎患者的临床疗效。方法82例患者随机分为对照组和观察组,每组41例,对照组给予美沙拉嗪肠溶片,观察组在对照组基础上加用实炎方,疗程8周。检测临床疗效、中医证候评分、炎症因子(白细胞介素-6、白细胞介素-22、白细胞介素-33)、肠黏膜屏障功能指标(二胺氧化酶、D-乳酸、内毒素)、肠道菌群(大肠杆菌、肠球菌、双歧杆菌、乳酸杆菌)、GQOLI-74评分变化。结果观察组总有效率高于对照组(P<0.05)。治疗后,2组中医证候评分、血清炎症因子、肠黏膜屏障功能指标降低(P<0.05),GQOLI-74升高(P<0.05),肠球菌减少(P<0.05),双歧杆菌、乳酸杆菌增加(P<0.05),以观察组更明显(P<0.05)。结论实炎方可提高溃疡性结肠炎患者生活质量,临床疗效明显。